Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, August 31, 2022

Aging, testosterone, and neuroplasticity: friend or foe?

 Ask your doctor what the full article says about using testosterone for neuroplasticity.

All this other stuff for your doctor to know about;

Well your doctor has a lot of studying to do. 

Testosterone Improves Woman’s Brain Functions

FDA Concludes Testosterone Use May Increase Risk of Cardiovascular Events

 

FDA warns about blood clot risk with testosterone products


Testosterone increases neurotoxicity of glutamate in vitro and ischemia-reperfusion injury in an animal model

 

Thinking with your gonads: testosterone and cognition

 

Effect of testosterone on functional recovery in a castrate male rat stroke model

 

Lower Testosterone Levels Predict Incident Stroke and Transient Ischemic Attack in Older Men

 

Could androgens maintain specific domains of mental health in aging men by preserving hippocampal neurogenesis?


Single-Dose Testosterone Administration Impairs Cognitive Reflection in Men

The latest here:

Aging, testosterone, and neuroplasticity: friend or foe?

Kiarash Saleki ORCID logo, Mohammad Banazadeh ORCID logo, Amene Saghazadeh and Nima Rezaei

Abstract

Neuroplasticity or neural plasticity implicates the adaptive potential of the brain in response to extrinsic and intrinsic stimuli. The concept has been utilized in different contexts such as injury and neurological disease. Neuroplasticity mechanisms have been classified into neuroregenerative and function-restoring processes. In the context of injury, neuroplasticity has been defined in three post-injury epochs. Testosterone plays a key yet double-edged role in the regulation of several neuroplasticity alterations. Research has shown that testosterone levels are affected by numerous factors such as age, stress, surgical procedures on gonads, and pharmacological treatments. There is an ongoing debate for testosterone replacement therapy (TRT) in aging men; however, TRT is more useful in young individuals with testosterone deficit and more specific subgroups with cognitive dysfunction. Therefore, it is important to pay early attention to testosterone profile and precisely uncover its harms and benefits. In the present review, we discuss the influence of environmental factors, aging, and gender on testosterone-associated alterations in neuroplasticity, as well as the two-sided actions of testosterone in the nervous system. Finally, we provide practical insights for further study of pharmacological treatments for hormonal disorders focusing on restoring neuroplasticity.


Corresponding author: Nima Rezaei, Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, 14197 33151 Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, 14176 13151 Tehran, Iran; and Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), 14197 33151 Tehran, Iran, E-mail:
Kiarash Saleki and Mohammad Banazadeh contributed equally to this work.

No comments:

Post a Comment